Hematology & Oncology Doctors in Salem, OR Accepting Medicare

5 Hematology & Oncology doctors found. Showing 1 - 5

Robert Francis Granatir, M.D. Internal Medicine - Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 3863 Saint Andrews Loop S, Salem, OR 97302 Phone: 503-364-0773

Dr. William C Pierce, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 875 Oak St Se, Suite 4030, Salem, OR 97301 Phone: 503-561-6444    Fax: 503-561-6440

John M Strother, M.D Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 875 Oak St Se, Suite 4030, Salem, OR 97301 Phone: 503-561-6444    Fax: 503-561-6440

Dr. Charles G Petrunin Ii, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 875 Oak St Se, Suite 4030, Salem, OR 97301 Phone: 503-561-6444    Fax: 503-561-6440

Dr. Natasha M Tiffany, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 875 Oak St Se, Suite 4030, Salem, OR 97301 Phone: 503-561-6444    Fax: 503-561-6440

News Archive

Praxis to provide patient recruitment services for international type 2 diabetes study

Praxis, a company specializing in centralized patient recruitment for clinical research studies, will provide patient recruitment services to a top 20 pharmaceutical company for an international study on type 2 diabetes. The study explores an investigational drug's effectiveness for maintaining glycemic control for individuals newly diagnosed with type 2 diabetes.

Eye color reflects a simple, predictable and reliable genetic pattern of inheritance

Before you request a paternity test, spend a few minutes looking at your child's eye color. It may just give you the answer you're looking for.

Maintaining a healthy diet can help prevent kidney disease, shows study

Maintaining a healthy diet may help prevent kidney disease, according to an analysis of published studies. The findings appear in an upcoming issue of CJASN.

Matching the right tumor with the right drug

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

U of O introduces Refugees and Global Health online program in Canada

All Canadian medical students, residents and practitioners now have full access to an innovative Web-based tool to enhance their understanding of medical care for refugees and new Canadians.

Read more Medical News

› Verified 5 days ago